Is this Monkey Business or What? The Return of Monkey Pox (M-Pox), By Brian Simpson
Many conservative writers have put the point of view that there will be new plandemic soon, as we have been warned of this by Bill Gates, the World Economic Forum and other globalists, just in time for massive electoral fraud in the US to deliver the cackling Kamala regime. It looked for a time like bird flu would be the one, but it has not moved quick enough, but no doubt a dangerous version could be released from a bioweapons lab if necessary.
Yet, the World Health Organization (WHO) has now moved to see monkey pox, now mpox, as the big threat, and is set to declare a global emergency: https://www.infowars.com/posts/its-official-un-set-to-declare-monkeypox-and-bird-flu-as-global-emergency-deploy-troops-worldwide/. The WHO has granted emergency listing for two new mpox vaccines. Like with the Covid mRNA vaxxes, this will speed up the process of delivering the vaccines to Africa, no doubt cutting out bothersome testing and trials.
The outbreak in Africa is mainly restricted to Democratic Republic of the Congo, and even then, is found predominantly in gay and bisexual men, as it was in the West. While sites such as Infowars.com see the potential for a repeat of the Covid plandemic, mpox seems to be the wrong virus for this. Bird flu, a genetically modified version would have been more to fear. But who knows, that may still be rolled out?
"The World Health Organization (WHO) today triggered the process to grant Emergency Use Listing to two monkeypox vaccines.
WHO Director-General Tedros Adhanom Ghebreyesus told the media the listing will accelerate vaccine access in lower-income countries that have not yet approved the drugs.
"Emergency Use Listing also enables partners including Gavi and UNICEF to procure vaccines for distribution," Tedros said. He also said he would convene an expert group to determine if the spread of monkeypox — renamed mpox — in Africa should be declared a global emergency.
Gavi, the Vaccine Alliance and UNICEF are funded in part by the Bill & Melinda Gates Foundation.
The WHO uses the Emergency Use Listing process to help member states that haven't already authorized unlicensed vaccines, therapeutics and tests speed up their processes for authorizing them.
During the COVID-19 pandemic Emergency Use Listing was a key mechanism used by member states without structures for granting emergency use authorization to drugs to authorize and distribute the vaccines, working together with the WHO, Gavi and UNICEF, Unlimited Hangout's Max Jones reported.
Tedros said the Emergency Use Listing helps those same partners procure vaccines for distribution, and that countries like Japan, the U.S. and the European Union are supporting the effort through donations.
He said the Democratic Republic of the Congo is experiencing a severe outbreak of mpox, with 14,000 cases and 511 deaths. Although cases have existed there for decades, the numbers are rising and spreading to new provinces, he said.
There have also been 50 confirmed cases reported in neighboring countries Burundi, Kenya, Rwanda and Uganda.
The illnesses, he said, are caused by a virus strain, or "clade," — clade 1b — that is more severe than clade 2, which was responsible for the global outbreak in 2022.
In 2022, WHO declared mpox to be a global emergency after reporting that it spread to more than 70 countries, mostly affecting gay and bisexual men. At the time, Tedros made the declaration unilaterally, in direct contradiction to independent review panel advice.
Out of concern with the current spread of monkeypox, Tedros announced the WHO has developed a $15 million response plan for surveillance, preparedness and response activities. The agency has already released $1 million from the WHO Contingency Fund for Emergencies to support scale-up of the response, with plans to release more in the coming days.
He also said he is convening an Emergency Committee under the International Health Regulations to advise him on whether the outbreak is a "public health emergency of international concern."
"The committee will meet as soon as possible and will be made up of independent experts from a range of relevant disciplines from around the world," Tedros said.
Safety and efficacy concerns with the vaccine
Symptoms of monkeypox infection are usually mild and include fever, rash and swollen lymph nodes, and occasionally intense headache, back pain, muscle aches, lack of energy and skin eruptions that can cause painful lesions, scabs or crusts.
The virus is "rarely fatal" and no deaths were reported in the U.S. as of Aug. 4, 2022.
Dr. Meryl Nass, an internist and biological warfare expert, told The Defender that in Africa, the disease has reportedly been more deadly. The numbers, she said, are difficult to confirm.
Tedros did not name the vaccines that will receive Emergency Use Listing, but Nass said there are two monkeypox vaccines: Jynneos and ACAM2000.
Both were originally approved to fight smallpox. Jynneos was licensed for monkeypox in the U.S. in 2019 — when no outbreak was ongoing. ACAM2000 has been "made available for use against mpox in the current outbreak [2022] under an Expanded Access Investigational New Drug (EA-IND) protocol."
The drugs cause myocarditis, pericarditis and other serious side effects at high rates, Nass said, as the labels for both drugs indicate.
Neither of the vaccines are approved for children under age 18, although in 2022, Jynneos received emergency use authorization in the U.S. for children under 18 considered to be at high risk.
Officials at the Africa Centers for Disease Control and Prevention (CDC) reported the majority of cases and deaths from monkeypox are in children under age 15.
Nass said that although in the U.S. monkeypox has appeared to be a mild illness, several lucrative government contracts have paid the vaccine makers hundreds of millions to stockpile the vaccines.
Nass also said there are serious questions about the efficacy of the vaccines. According to the labels, the efficacy rates are inferred based on immunogenicity studies, which study antibody responses, rather than testing whether a vaccine protects against disease.
The U.S. CDC said the vaccines are "expected to be effective" against both clades of monkeypox infection.
The Poxvirus and Rabies Branch of the Africa CDC, which has done much of the monkeypox vaccine safety and efficacy research in the Democratic Republic of Congo, did not immediately respond to questions about the efficacy and safety of the vaccines."
https://www.malone.news/p/the-new-mpox-scare
"Why the sudden interest in mpox?
An article quickly compiled by Science magazine explains that the more deadly variant is spreading in Africa.
But of course, the main thrust of the article is actually this:
The World Health Organization (WHO) is appealing for more help after the troubling development, which it fears could be a precursor to a new mpox epidemic, just 2 years after a milder strain spread worldwide. "A further scaling up of the mpox response underway in affected countries is urgently needed amid the expanding outbreak," WHO Director-General Tedros Adhanom Ghebreyesus said in a statement to ScienceInsider. Tedros noted that WHO is working with local health officials, the Africa Centres for Disease Control and Prevention (Africa CDC), and international partners to slow transmission. "But much more funding for a comprehensive response, including for diagnostics, therapeutics, and vaccines, is urgently needed," he said.
But the reporting page on the WHO actually reports that:
With the exception of countries3,4 in West and Central Africa, amongst those countries for whom mpox cases' exposures have been reported, the ongoing outbreak of mpox continues to primarily affect men who have sex with men (MSM). At present there is no signal suggesting sustained transmission beyond these networks. Confirmation of one case of mpox, in a country, is considered an outbreak.
So, according to the WHO's own document, for men having sex with men who have other chronic immunosuppressive diseases, such as HIV, mpox may be a real threat. But for the rest of us, not so much.
Interesting to note that the confirmation of a single case in a country meets the definition of an outbreak by the WHO.
Although, the exact ratio is not known, the majority of cases are asymptomatic. So, the mortality rate is not known.
In the USA, there have been 32,063 confirmed cases of mpox, with 58 deaths (most of these men, if not all, were immunosuppressed -HIV positive). So, most, if not all of these deaths was not actually of mpox - but with mpox.
As usual, this is really about money, power, and subsidies.
Per the Daily Mail, which specializes in Fearporn as a key part of its business model-
As part of WHO's regional response, Dr Adhanom Ghebreyesus said it does not recommend travel restrictions on affected countries and it is requesting $15million from the United States to support surveillance, preparedness and response actions.
The WHO is providing $1million to increase its response to the spread and is coordinating with humanitarian groups to get access to and distribute vaccines to affected areas.
Two vaccines have been backed by the WHO to prevent Mpox infection. The organization recommends a vaccine within four days of contact with someone who has the virus or within up to 14 days if there are no symptoms.
Healthcare workers and men who have sex with men are advised to receive a vaccine even if they have had no Mpox exposure.
Symptoms of Mpox include a rash, skin lesions, fever, headache, muscle aches, back pain and swollen lymph nodes.
It is spread through physical contact, such as kissing or sex, animals when cooking them, contaminated materials and pregnant women who can spread it to a fetus.
There is no direct cure for Mpox, but doctors aim to treat it s symptoms, including clearing up the rash and managing pain."
Comments